Parameter
| Biomarker | Atezolizumab-Bevacizumab Response Signature (ABRS) | Full name | Atezolizumab-Bevacizumab Response Signature | Molecular Type | Nucleic acid (RNA signature) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Predicting treatment response | ||
| Disease | Hepatocellular Carcinoma (HCC) | Disease Subtypes | / | ||
| Organ | Liver | Test Sample / Technology Platform | Tumor tissue (RNA-seq) | ||
| Pathobiological Mechanisms | Based on multi-gene expression characteristics, it reflects the status of tumor immunity and angiogenesis | ||||
| Clinical Availability Status | Research validation: high expression patients received combination therapy PFS is prolonged | ||||
| Notes and Dynamics | This study provides a molecular basis for the selection of patients for combination therapy | ||||